If you've ever asked for a blood test "to see if I'm in perimenopause" and been told the test isn't useful, this is why. FSH and LH aren't the hormones that make you feel anything — they're the brain's signal asking the ovaries to ovulate, and they swing wildly through perimenopause. A single number on a single day rarely tells you what your symptoms, your cycle pattern and your age can already tell a menopause-trained doctor. The test does become genuinely useful in a few specific situations, which the page below walks through.
FSH and LH in three answers.
What it does
Follicle-stimulating hormone (FSH) and luteinising hormone (LH) come from the pituitary gland in your brain, not the ovaries. They're the messages the brain sends DOWN to ask the ovaries to ovulate. As ovaries get less responsive, the brain shouts louder — which is why FSH rises in perimenopause and stays high in menopause.
What changes in perimenopause
FSH levels swing wildly through perimenopause, sometimes high, sometimes back to a 'reproductive' range within weeks. A single 'normal' FSH does NOT rule out perimenopause. A single 'high' FSH doesn't confirm it either. This is why most menopause societies recommend diagnosing perimenopause from your symptoms and your age, not from a one-off blood test.
Where you'll feel it
You don't, directly. You feel the consequences (the estrogen and progesterone swings these hormones drive). FSH/LH matter mainly when investigating premature menopause (under 40), unusual presentations, or to monitor very specific treatments.
What to say out loud.
If a doctor offers a single FSH test to 'check if you're in menopause' and you're between 45 and 55 with the symptoms, the guideline answer in most countries is that the test isn't needed. Under 40, or with surgery or chemotherapy in the picture, the test is more useful and may be repeated.
Pick the part you came for.
4 sections. Open one, skip the rest — nothing here depends on reading in order.
Why a single FSH test is so often misleading
The lab number you've probably been quoted
FSH rises in perimenopause because the ovaries become less responsive — the brain has to shout louder to get a follicle to mature. The catch is that perimenopausal FSH swings: it can be 'menopausal' one week and 'reproductive' three weeks later, depending on where you are in a cycle that may itself be irregular. A single high reading does not confirm menopause; a single normal reading does not rule out perimenopause.
Read the rest
This is why every major guideline (NICE, NAMS, IMS, BMS) recommends diagnosing perimenopause from age and symptoms in women between 45 and 55, not from a one-off FSH. The test mainly earns its keep in three situations: suspected premature ovarian insufficiency (under 40), unusual presentations, and monitoring after specific treatments.
When the test is genuinely useful
Premature ovarian insufficiency, surgical menopause, and the cancer-treatment context
Under 40 with absent or very irregular periods plus menopausal symptoms is the textbook indication: two FSH levels at least 4 to 6 weeks apart, both elevated, supports a diagnosis of premature ovarian insufficiency (POI). POI is not the same as 'early menopause' — it has implications for fertility, bone, cardiovascular and brain health that need a specialist plan, not reassurance.
Read the rest
FSH and LH also have a role in monitoring after chemotherapy- or radiation-induced ovarian shutdown, after some forms of GnRH-agonist treatment, and in people on testosterone-blocking therapy. In these contexts the numbers tell a real story; in the routine 'am I in perimenopause' context they usually don't.
AMH and the 'ovarian reserve' question
Useful for fertility, much less useful for menopause timing
Anti-Müllerian hormone (AMH) is sometimes folded into the same conversation. It correlates better with ovarian reserve than FSH and is widely used in fertility clinics. For predicting how soon you will reach menopause, AMH is better than nothing but is still imprecise — typically able to suggest 'within a few years' rather than a date. It does not replace the symptom-and-age conversation.
Tests you'll see marketed: DUTCH and 'adrenal fatigue'
What these panels can and can't tell you
Two tests come up a lot in perimenopause: the DUTCH panel (Dried Urine Test for Comprehensive Hormones), and salivary cortisol panels sold as a way to check for 'adrenal fatigue'. Both measure something real. The question is what you can fairly conclude from the result.
Read the rest
DUTCH measures urinary metabolites of estrogen, progesterone, androgens and cortisol over a 24-hour collection, and it's a genuine research tool. Where it gets shaky is interpretation: reference ranges for most of those metabolites aren't standardized across labs, and they don't map neatly onto how a symptomatic perimenopausal woman actually feels. That's why no major menopause or endocrine body (NAMS, IMS, BMS, the Endocrine Society) uses it to diagnose perimenopause or set an HRT dose. A tidy-looking result won't rule perimenopause out, and a messy-looking one won't tell you how much estradiol you need.
Salivary cortisol is a different animal. It's a low-burden, repeatable way to map your daily cortisol curve, and it's used in real clinical and research settings, including late-night salivary cortisol screening for Cushing's syndrome. If you're tracking one, that's a reasonable thing to do. What a curve can't do on its own is confirm the gland-exhaustion version of 'adrenal fatigue', and that's where the supplement protocols usually get attached. Bring the curve to someone who can put it next to the rest of your picture.
Here's the part that matters most: the exhaustion is real. Fatigue is one of the most consistently reported symptoms in every long-term study of this transition, and it has plenty of mechanisms behind it, including broken sleep, swinging estrogen and progesterone, mood load, and ADHD that's lost its hormonal scaffolding. It deserves a proper workup. Usually that means thyroid, ferritin, B12, vitamin D, sleep, mood, and a conversation about whether HRT is on the table. If someone leads with a panel, a fair and friendly question is: what would you do differently based on this result?
8 sources behind this pagePrimary papers and guidelines only. Each card opens the original.
Diagnose perimenopause and menopause in women aged over 45 from symptoms alone; do not routinely use FSH to diagnose menopause in this group.
The most-cited statement in modern menopause primary-care guidance.
Read the sourceSingle FSH measurements show high within-woman variability across the menopause transition; serial measurements weeks apart are more informative.
Hall et al · Study of Women's Health Across the Nation
Read the sourcePremature ovarian insufficiency is diagnosed by two elevated FSH levels at least 4–6 weeks apart in women under 40 with menstrual disturbance and menopausal symptoms.
POI carries fertility, cardiovascular and bone implications that go beyond a 'low FSH = menopause' framing.
Read the sourceAMH offers a modest improvement over FSH in predicting time to menopause but is not precise enough to give a date.
The gland-exhaustion version of 'adrenal fatigue' isn't a recognized medical diagnosis, and there's no evidence that long-term stress causes the adrenal glands to under-produce cortisol in that way. Salivary cortisol panels can map a daily curve, but they aren't a standalone diagnostic for that claim.
Plain-English statement from the international endocrinology society. Useful to read before paying for a four-point cortisol curve.
Read the sourceA systematic review of 58 studies found no substantiation of 'adrenal fatigue' as a medical condition; cortisol assessment methods varied widely and produced contradictory results.
Cadegiani & Kater
Read the sourceUrinary hormone metabolite panels (including dried-urine formats marketed as DUTCH) are not endorsed by major menopause societies as a basis for diagnosing perimenopause or guiding MHT dosing; symptom-based diagnosis remains the standard of care in women aged 45–55.
Neither NICE nor NAMS lists urinary metabolite panels as a recommended diagnostic. Read alongside the NAMS compounded-BHRT statement, which addresses the related practice of prescribing custom hormones off the back of these results.
Read the sourcePerimenopause stages clinically using STRAW+10: variable cycle length and skipped cycles in late perimenopause, with diagnosis driven by symptom pattern and cycle history rather than a single hormone test.
Santoro N
The plain-clinician summary of STRAW+10 staging that most modern menopause writing leans on. Useful to send a doctor who's still looking for one definitive blood test.
Read the sourceRelated